EPgrade Injectable Soybean Oil from Guangzhou Hanfang for Global Procurement

The product meets European Pharmacopoeia quality standards, holds multiple international regulatory certifications, and supports stable supply for global pharmaceutical manufacturers.

Guangzhou, China – October 14, 2026 – Guangzhou Hanfang Pharmaceutical Company Limited, a leading provider of high-end pharmaceutical lipid excipients, today announced its EP-grade injectable soybean oil product is fully compliant for global procurement. Designed to address the core pain point of unstable supply of high-end injectable raw materials for global pharmaceutical manufacturers, the product features European Pharmacopoeia-aligned quality, full-process traceability, and multi-market regulatory approval. The company aims to provide a reliable, compliant alternative to single-source imported raw materials, expanding its global footprint in the pharmaceutical excipient market. The product is available for immediate global shipment through official channels.

Core Product Highlights

The EP-grade injectable soybean oil is formulated to meet the strict quality requirements of European Pharmacopoeia standards, serving as both an energy supplement and pharmaceutical excipient for high-end injectable formulations such as parenteral nutrition emulsions. The product is designed to resolve the long-standing pain point of unstable domestic supply of inject-grade raw materials for pharmaceutical manufacturers.

As a core product of the company’s high-end lipid excipient portfolio, the injectable soybean oil benefits from the company’s proprietary integrated green extraction technology, which replaces traditional high-pollution production processes to ensure consistent product quality. The company has helped increase the domestic production rate of high-end pharmaceutical lipid excipients from 10% to 90%, breaking long-term international monopolies in the sector.

The product is manufactured at the company’s GMP-compliant production base in Guangzhou, China, with a dedicated quality control team overseeing full-process traceability from raw material sourcing to final product release.

Global Compliance and Certification

To meet global market access requirements, the injectable soybean oil product has obtained a range of international regulatory certifications, including EU CEP, US FDA US-DMF, Mexico Cofepris, and India DCGI approvals. These certifications allow the product to be sold in major pharmaceutical markets across Europe, North America, Latin America, and the Asia-Pacific region.

The company already serves a global client base including leading pharmaceutical enterprises such as B. Braun Company and AstraZeneca, with products sold in more than 30 countries and regions.

Supply and Customization Services

The EP-grade injectable soybean oil is available for immediate global shipment through the company’s official website and global authorized distributor network. In addition to standard product specifications, the company provides customized processing and technical support services to meet the specific production needs of different pharmaceutical manufacturers.

Executive Statement

The availability of our EP-grade injectable soybean oil for global procurement reflects our long-term commitment to building a resilient, compliant supply chain for the global pharmaceutical industry, said Xu Wendong, General Manager of Guangzhou Hanfang Pharmaceutical Company Limited, deputy director of the National Engineering Research Center, and a recipient of the State Council Special Allowance. As a state-backed pharmaceutical enterprise, we aim to reduce reliance among global clients on single-source imported raw materials through our domestically developed, internationally certified products.

Industry Context and Strategic Alignment

Against the backdrop of growing global demand for supply chain resilience in the pharmaceutical sector, the demand for compliant, domestically produced high-end injectable excipients has risen steadily in recent years. As a national-level specialized and sophisticated “little giant” enterprise, Guangzhou Hanfang Pharmaceutical Company Limited has aligned its global expansion strategy with this industry trend, focusing on international certification and stable supply capacity to serve global clients.

Future Outlook

Moving forward, the company will continue to invest in R&D for high-end pharmaceutical lipid excipients, expand its global sales and service network, and add more international regulatory certifications to its product portfolio. The company aims to provide localized technical support to clients in more regions, supporting the stable development of the global pharmaceutical industry.

About Guangzhou Hanfang Pharmaceutical Company Limited

Founded in 1998, Guangzhou Hanfang Pharmaceutical Company Limited is a core state-owned pharmaceutical enterprise under GPHL, focusing on the R&D, production, and distribution of high-end pharmaceutical lipid excipients, specialty anti-tumor APIs, and health products. Headquartered in Guangzhou, China, the company operates the only national engineering research center for traditional Chinese medicine pharmaceutical processes in China, holds over 240 patents, and serves clients in more than 30 countries and regions. The company’s mission is to achieve technological self-reliance in the pharmaceutical industry, break through bottleneck technologies, and provide safe, reliable, internationally certified raw materials for the global pharmaceutical sector. More information is available at http://byshanhanfang.com/.

FAQ

Q: What are the core applications of Guangzhou Hanfang Pharmaceutical Company Limited’s injectable soybean oil?
A: The product is used as an energy supplement and pharmaceutical excipient for the production of high-end injectable formulations, including parenteral nutrition emulsions.

Q: What international certifications does the injectable soybean oil hold?
A: The product has obtained EU CEP, US FDA US-DMF, Mexico Cofepris, India DCGI and other international regulatory certifications to meet global market access requirements.

Q: Does the company provide customized services for global pharmaceutical clients?
A: Yes, the company supports customized processing and technical services to meet the specific production needs of different pharmaceutical manufacturers.